Geratherm Medical AG

Earnings Release • Nov 25, 2003

News Details

Ad-hoc | 25 November 2003 08:27

Geratherm: Q3 2003 Group period results more than doubled to reach EUR 429,000

Ad-hoc-announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. ——————————————————————————– 3rd quarter 2003 Group period results more than doubled to reach EUR 429,000 ·turnover +8%; EBIT +14%; earnings per share: EUR 0.10 (last year: EUR 0.04 ) ·3rd clinical trial of the Cardio-Monitor concluded successfully Geratherm Medical AG: 25. November 2003. The third quarter was successful for Geratherm Medical. The turnover of the third quarter increased by 8%, as compared to the same period of the previous year. As per September 30, a turnover of EUR 5.5 million (last year EUR 5 million) could be reached for the first 9 months. Following the weaker two first quarters, the earnings quality recovered clearly during the third quarter. Given an operative margin of 20%, earnings before interest and tax (EBIT) could be increased by 14% to reach EUR 245,000. Altogether, the accumulated operating results as per September 30 stand at EUR 404,000 TEUR, and are thus still 42% lower than the comparative period of last year. However, we expect that the operating results will reach the good level of the previous year throughout the course of the fourth quarter. Apart from a clearly increasing contribution by the operational results, a financial result of EUR 138,000 could be achieved, so that the result of ordinary business operations of EUR 383,000 (last year EUR 137,000) more or less tripled in the third quarter, as compared to the same quarter of the previous year. The Group period results of the third quarter amounted to EUR 429,000 (last year: EUR 191,000) or EUR 0.10 per share. Cumulatively, Geratherm Medical was able to achieve an after-tax result of EUR 926,000 or EUR 0.21 per share (previous year EUR 0.19) by September 30, 2003. One of the main new developments of Geratherm Medical, the AFD-Monitor for the early detection of stroke risks and atrial fibrillation, was able to achieve very good clinical results in a larger cardiological study with more than 50 patients. The start of marketing is scheduled for the end of the first quarter 2004. Geratherm Medical AG, listed in the Prime Standard, develops, produces and sells systems for the measurement and transfer of vital data. Geratherm Medical AG, Fahrenheitstrasse 1, 98716 Geschwenda, Germany Editor: Martina Schramm, Phone: +49(0)36205/98 111, Fax: +49(0)36205/98 115 E-Mail: info@geratherm.com – end of release end of ad-hoc-announcement (c)DGAP 25.11.2003 ——————————————————————————– WKN: 549562; ISIN: DE0005495626; Index: Listed: Amtlicher Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin- Bremen, Düsseldorf, Hamburg, München und Stuttgart 250827 Nov 03